PGS para Anomalías Cromosómicas -

What is PGS (Preimplantation Genetic Screening) for chromosomic anomalies?


Preimplantation genetic screening (PGS) for aneuploidy is a powerful genetic test that may be performed on embryos during IVF treatment to screen for numerical chromosomal abnormalities.

PGS is performed on a small embryo biopsy prior to transfer and identifies which embryos are chromosomally normal.

Chromosomally normal embryos are the most likely to develop to term and to be born as a healthy baby.

PGS testing helps IVF physicians and patients decide which embryos to transfer.

This procedure allows us to analyze all 24 chromosome types in order to discard the possibility of embryonic aneuploidy before implantation.

PGS offers comprehensive analysis of all 24 chromosome types: the two sex chromosomes (X and Y) and the 22 other non-sex chromosomes. Normally there are 23 pairs of chromosomes in each human cell. A numerical change in the number of chromosomes is called aneuploidy. Aneuploidy is responsible for the vast majority of spontaneous miscarriages and can result in birth defects and mental retardation in live born babies. Most types of aneuploidy are not compatible with life. The most common syndromes caused by non-sex chromosome aneuploidies are Down syndrome, Edwards syndrome, and Patau syndrome. Aneuploidy is usually not inherited and can involve any chromosome; however, the likelihood of embryos to be aneuploid increases with the age of the mother.

More information

Biofertility uses array CGH (comparative genomic hybridization) technology to perform PGS for aneuploidy screening. Our team works with BlueGnome’s 24sure BAC-based arrays. This technology is specially developed for analysis of only a few cells or even a single cell as is required for preimplantation genetic testing.

Validation studies have been performed in our laboratory to optimize DNA quality and amplification. PGS testing with array CGH is 98-99% accurate.

What are the benefits of PGS?

The majority of abnormal embryos are indistinguishable from normal embryos when studied using a microscope. Therefore, normal embryo appearance cannot be used to evaluate for chromosome abnormalities. For women in their mid thirties and older, the risk of chromosome abnormalities is significantly higher than for younger women. Women with a history of recurrent miscarriage or recurrent implantation failure, or who have had a prior pregnancy with a chromosome abnormality, or men with abnormal sperm analysis may also create a higher percentage of abnormal embryos.

Improve your reproductive success with the specific selection of chromosomally normal embryos The main benefits of PGS for chromosome abnormalities include increase in implantation rate, reduction in miscarriage rate, and increase in the chance of delivering a healthy baby:

Increase in implantation rate: Some embryos that are chromosomally abnormal will fail to implant into a woman’s uterus. Therefore, by transferring chromosomally normal embryos, PGS using an array can increase the implantation rate.

Reduction in miscarriage rate: In the general population, 20% of all clinical pregnancies miscarry and about half are chromosomally abnormal. Since PGS evaluates numerical changes in chromosome numbers and large chromosome imbalances, embryos with chromosome abnormalities will not be transferred. Therefore, especially, in high-risk groups, PGS reduces the risk of miscarriage.

Increase in the chance of delivering a healthy baby: Some pregnancies with chromosome abnormalities will result in the birth of a child with multiple serious anomalies. Therefore, PGS can increase the chance of delivering a healthy baby by assisting physicians in identifying chromosomally healthy embryos for transfer. These conditions can also be detected by chorionic villus sampling (CVS) or amniocentesis later during the pregnancy.

Who should use PGS testing?

Over 50% of spontaneous miscarriages are caused by chromosomal abnormalities. Some birth defects are caused by chromosome abnormalities, and the risks of having a child with a chromosome abnormality increases with maternal age. Couples who are at increased risk of having aneuploidy embryos should consider using PGS testing. These groups of individuals include:

Women over 35 years of age
Couples who have experienced several spontaneous miscarriages of unknown cause Couples with several cycles of IVF that have not achieved pregnancy Men with low sperm concentration Couples with a previous pregnancy with chromosomal abnormality

The selection of chromosomally normal embryos in these couples greatly reduces the risk of miscarriage and increases reproductive success.

Delayed Maternity (Advanced Maternal Age)

The rhythm of life has caused more and more women to decide to become mothers later in life when their fertility has been reduced. A woman is born with a certain number of eggs, and her ability have children decreases over her lifetime, in part because the chance of chromosome abnormalities also increases as she ages. Most embryos with an incorrect number of chromosomes fail to implant or miscarry during the first trimester of pregnancy. The decline in fertility is gradual, but many medical providers consider the risks of chromosome abnormalities to be significant at age 35 or older. Chromosome abnormalities in live borns can cause conditions such as Down Syndrome (three copies of chromosome 21 instead of two), Edwards syndrome, and Patau syndrome.

Who should use PGS testing?

Over 50% of spontaneous miscarriages are caused by chromosomal abnormalities. Some birth defects are caused by chromosome abnormalities, and the risks of having a child with a chromosome abnormality increases with maternal age. Couples who are at increased risk of having aneuploidy embryos should consider using PGS testing. These groups of individuals include:

Approximately 50% of spontaneous miscarriages occur in the first trimester because of random (de novo) chromosome abnormalities. PGS studies in these couples have revealed that 65% of embryos are chromosomally abnormal, and in 15% of couples, all embryos are chromosomally abnormal. PGS evaluates all 24 chromosomes to detect any numerical chromosome abnormality.

Clinical studies of the IVI Group until 2012 show that the application of this technique doubles pregnancy rates obtained compared to 30% obtained without performing PGS*.

(*)Based on clinical studies performed by the IVI group up to 2012

Recurrent Implantation Failure

Sometimes, even when the egg is successfully fertilized and developing normally, it will not be able to implant into the uterus. This is called implantation failure and may occur because of abnormalities of either the uterus or the embryo itself. If chromosomal abnormalities are impacting embryo viability, the selection of chromosomally normal embryos will improve the chances of implantation and ongoing pregnancy. For couples who experience recurrent implantation failure, about 65% of embryos are expected to be abnormal.

Biofertility offers different techniques for couples experiencing implantation failure to increase their reproductive success. 

Male Infertility

Male reproduction requires good sperm quality and quantity. In cases of severe male infertility, Igenomix can perform sperm chromosome studies (see Sperm Aneuploidy Test), we know that low sperm count increases the percentage of chromosomally abnormal sperm and therefore increases the risk of producing aneuploid embryos. PGS for aneuploidy screening to identify chromosomally normal embryos may increase pregnancy success for couples where the man has an abnormal sperm analysis. For couples who experience male-factor infertility, approximately 55-65% of embryos may be chromosomally abnormal, depending on the severity of the male factor.

4. ¿Por qué realizar el PGS para anomalías cromosómicas con Biofertility?

Robust and reliable technology using BlueGnome’s cutting-edge 24sure arrays (aCGH)
Comprehensive analysis of all 24 chromosomes
Experienced genetic counselors
Senior team who analyze results for every embryo
Banking/batching program for low responders
12 hour protocol allowing results to be provided the morning after the biopsy
Double signature on all result reports Training of embryologists
Guaranteed outstanding customer service


1. What is embryo biopsy? Is the embryo damaged during the biopsy?

Embryo biopsy is the removal of one or just a few cells from the embryo (depending on the stage of development). If the embryo is handled correctly by a skillful embryologist, the embryo develops normally after embryo biopsy. Published studies demonstrate that there is no increased rate of birth defects in IVF babies that are born after biopsy compared to IVF babies that are born without embryo biopsy.

2. Can biopsy be done on day 3 or blastocyst stage (day 5)?

Biofertility can perform PGS testing on embryos that are biopsied at either day 3 or day 5. A 3 day old embryo has approximately 8 cells, and so only a single cell is removed for a biopsy done at day 3. A 5 day old embryo has a few hundred cells, and so several cells can be safely removed during the biopsy. There are several good reasons to do either a day 3 or a day 5 biopsy. The number of cells that can be safely removed, rates of mosaicism, expertise of the embryologist, and embryo quality are all important factors in deciding when to do embryo biopsy. Patients should discuss with their IVF doctor the best time to do the biopsy.

3. Does PGS include all genetic diseases?

No genetic test can detect all potential genetic abnormalities. PGS testing for aneuploidy can only assess numerical changes in chromosome number and other imbalances in genetic material including deletions and duplications. PGS will identify any missing or extra chromosomes, deletions, duplications, and unbalanced rearrangements that are larger than our detection limit of 6 Mb. PGS for aneuploidy screening cannot rule out single gene disorders, balanced structural abnormalities, uniparental disomy, and genetic imbalances including deletions and duplications smaller than our detection limit of 6 Mb. PGS can detect some types of polyploidy but cannot detect polyploidy in which the sex chromosomes are found as a multiple of normal (triploidy 69,XXX and tetraploidy 92,XXXX or 92,XXYY).

4. What is the effectiveness of CGH arrays for different indications?

When an embryo is identified as normal after PGS testing, the likelihood of a pregnancy is higher than 60% in women younger than 40 years. In women over 40 years, there is a higher percentage of cycles in which all embryos are abnormal, but when normal embryos are found, the likelihood of pregnancy is about 50%.

5. How many embryos are expected to be normal when using PGS?

The likelihood that embryos will be chromosomally normal decreases as women get older. According to data generated at Igenomix, the average percentages of normal embryos are:

BioFertility cannot guarantee that there will be normal embryos for any PGS test.

6. If PGS testing is done, is prenatal testing recommended?

Although PGS for aneuploidy screening is highly accurate, there is still a chance of misdiagnosis. PGS cannot detect mosaicism in the embryo because only a single cell or just a few cells are analyzed. Prenatal testing is recommended to confirm the results of PGS testing and may detect other abnormalities not tested for by PGS. Pregnant mothers should discuss options for prenatal testing with their obstetrician.

es_MXSpanish en_USEnglish
Abrir chat
Hi, how can we help you?
Write directly to our Whatsapp.